Efinaconazole was approved by the U.S. Food and Drug Administration (FDA) on July 31, 2014 [1]. It is a topical prescription medication used to treat onychomycosis, a fungal infection of the toenail [2].
When does efinaconazole's patent expire?
The primary patent for efinaconazole, U.S. Patent No. 8,338,451, was issued in December 2012 [3]. Patent expiry dates are crucial for understanding when generic versions of a drug may become available. Information on efinaconazole's patent status and potential future market entry for generics can be found on DrugPatentWatch.com [4].
What are the side effects of efinaconazole?
Common side effects associated with efinaconazole include application site redness, itching, and stinging or burning of the skin [2]. Less common side effects may also occur.
How is efinaconazole used to treat toenail fungus?
Efinaconazole is applied directly to the affected toenail and surrounding skin as a solution. Treatment duration and frequency are typically determined by a healthcare provider, but it is usually applied once daily for 48 weeks [2].
Are there other treatments for toenail fungus?
Yes, other topical and oral antifungal medications are available for treating onychomycosis. The choice of treatment depends on the severity of the infection, the specific fungus involved, and the patient's overall health. Oral medications, such as terbinafine or itraconazole, are often more effective but carry a higher risk of side effects and drug interactions [5]. Topical treatments like ciclopirox and efinaconazole offer an alternative with potentially fewer systemic risks [2, 5].
What is efinaconazole's mechanism of action?
Efinaconazole is an azole antifungal agent. It works by inhibiting the enzyme lanosterol 14α-demethylase, which is essential for ergosterol synthesis in fungal cell membranes. Disrupting ergosterol synthesis weakens the fungal cell membrane, leading to cell death [6].
Who manufactures efinaconazole?
Efinaconazole is marketed under the brand name Jublia by Bausch Health Companies Inc. [1].
What clinical data supports efinaconazole's efficacy?
Clinical trials have demonstrated the efficacy of efinaconazole in treating onychomycosis. Studies showed significant improvements in mycological cure rates and clinical cure rates compared to placebo [2, 7]. For example, in one study, mycological cure rates at 48 weeks were higher for efinaconazole compared to vehicle control [7].
What are the regulatory approvals for efinaconazole?
In addition to its U.S. FDA approval in 2014, efinaconazole has received marketing authorization in other regions, including Canada [8].
What is the pricing and insurance coverage for efinaconazole?
The cost of efinaconazole can vary significantly based on pharmacy, insurance coverage, and dosage. Patients may inquire about prescription drug plans and patient assistance programs to help manage the cost [9].
---
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-approvals-and-certifications
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/jublia-efinaconazole-solution-drug-safety-labeling-changes-2017
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/drug/efinaconazole
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701176/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417705/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184624/
[8] https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-database/drug-product-details.html?dptId=28585
[9] https://www.goodrx.com/jublia